These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30677239)

  • 1. Clinical outcomes of patients with active rheumatoid arthritis with normal acute phase reactant values.
    Chung MK; Park B; Kim IJ; Cho SK; Kim D; Sung YK; Choi CB; Choe JY; Chung WT; Hong SJ; Kim TH; Koh E; Lee SS; Yoon BY; Park H; Bae SC; Lee J
    Int J Rheum Dis; 2019 May; 22(5):852-859. PubMed ID: 30677239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year.
    Kay J; Morgacheva O; Messing SP; Kremer JM; Greenberg JD; Reed GW; Gravallese EM; Furst DE
    Arthritis Res Ther; 2014 Feb; 16(1):R40. PubMed ID: 24485007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registry.
    Kavanaugh A; Keystone E; Greenberg JD; Reed GW; Griffith JM; Friedman AW; Saunders KC; Ganguli A
    Rheumatology (Oxford); 2017 Jul; 56(7):1095-1101. PubMed ID: 28340006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Older age at rheumatoid arthritis onset and comorbidities correlate with less Health Assessment Questionnaire-Disability Index and Clinical Disease Activity Index response to etanercept in the RADIUS 2 registry.
    Martin WJ; Shim M; Paulus HE; Chaudhari S; Feng J; Elashoff D; Hahn TJ; Ranganath VK;
    J Clin Rheumatol; 2014 Sep; 20(6):301-5. PubMed ID: 25160011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of treatment options after conventional DMARDs failure in rheumatoid arthritis.
    Sung YK; Cho SK; Kim D; Choi CB; Won S; Bang SY; Cha HS; Choe JY; Chung WT; Hong SJ; Jun JB; Kim HA; Kim J; Kim SK; Kim TH; Lee HS; Lee J; Lee J; Lee SS; Lee SW; Lee YA; Nah SS; Suh CH; Yoo DH; Yoon BY; Bae SC;
    Rheumatol Int; 2017 Jun; 37(6):975-982. PubMed ID: 28132102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The influence of age at disease onset on disease activity and disability: results from the Ontario Best Practices Research Initiative.
    Ruban TN; Jacob B; Pope JE; Keystone EC; Bombardier C; Kuriya B
    Clin Rheumatol; 2016 Mar; 35(3):759-63. PubMed ID: 26245721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
    Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC
    Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of cytokine profiles in rheumatoid arthritis patients with clinically active disease and normal inflammatory indices.
    Alex AM; Sayles H; Mikuls TR; Kerr GS
    Clin Rheumatol; 2019 Apr; 38(4):1075-1081. PubMed ID: 30506404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined measurement of multiple acute phase reactants to predict relapse of rheumatoid arthritis.
    Lv F; Song LJ; Li XF
    Int J Rheum Dis; 2015 Sep; 18(7):725-30. PubMed ID: 24131533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.
    Shadick NA; Gerlanc NM; Frits ML; Stolshek BS; Brady BL; Iannaccone C; Collier D; Cui J; Mutebi A; Weinblatt ME
    Clin Rheumatol; 2019 Nov; 38(11):3081-3092. PubMed ID: 31353421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of patients with rheumatoid arthritis in Qatar: a cross-sectional study.
    Lutf A; Poil AR; Hammoudeh M
    Int J Rheum Dis; 2014 Jan; 17(1):63-5. PubMed ID: 24472269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.
    Aletaha D; Nell VP; Stamm T; Uffmann M; Pflugbeil S; Machold K; Smolen JS
    Arthritis Res Ther; 2005; 7(4):R796-806. PubMed ID: 15987481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparative responsiveness of the patient self-report questionnaires and composite disease indices for assessing rheumatoid arthritis activity in routine care.
    Salaffi F; Ciapetti A; Gasparini S; Carotti M; Bombardieri S;
    Clin Exp Rheumatol; 2012; 30(6):912-21. PubMed ID: 22935335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study.
    Al-Gareeb AIA; Gorial FI; Mahmood AS
    Clin Rheumatol; 2018 Oct; 37(10):2633-2641. PubMed ID: 29882203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with quality of life and functional disability among rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs for at least 6 months.
    Bae SC; Cho SK; Won S; Lee HS; Lee SH; Kang YM; Lee SH; Lee YA; Choe JY; Chung WT; Suh CH; Shim SC; Lee J; Yoon BY; Kim DW; Lee SS; Yoo WH; Kim JS; Jung YO; Nah SS; Lee CK; Song GG; Choi SJ; Joung CI; Koh H; Kim YJ
    Int J Rheum Dis; 2018 May; 21(5):1001-1009. PubMed ID: 29878615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Response Criteria in Rheumatoid Arthritis Treated With Biologic Disease-Modifying Antirheumatic Drugs.
    Inoue M; Kanda H; Tateishi S; Fujio K
    Arthritis Care Res (Hoboken); 2020 Jul; 72(7):942-949. PubMed ID: 31058442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tocilizumab in refractory rheumatoid arthritis: a real life cohort from a single centre.
    Addimanda O; Possemato N; Macchioni P; Salvarani C
    Clin Exp Rheumatol; 2014; 32(4):460-4. PubMed ID: 24960220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
    Choy EH; Bernasconi C; Aassi M; Molina JF; Epis OM
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
    Smolen JS; Aletaha D
    Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.